This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other specified congenital malformation syndromes, not elsewhere classified기타 명시된 선천기형증후군

ItemDetails
A. Classification codesICD-10: Q87.8 | Special Copayment Reduction: V267 | Re-approval cycle: 5 years
B. SynonymsAlport syndrome, Laurence-Moon(-Bardet)-Biedl syndrome (Bardet-Biedl syndrome), Zellweger syndrome, CHARGE syndrome
C. Adult onsetAlport syndrome is sometimes first confirmed in adulthood with end-stage renal disease; Bardet-Biedl syndrome is diagnosed in childhood with complex complications persisting into adulthood; CHARGE syndrome is in principle diagnosed in childhood; Zellweger syndrome mostly results in death in the neonatal period to infancy
SectionSummary
1. HistoryAfter the clinical descriptions of Alport (1927 Alport), Bardet-Biedl (1920/1922 Bardet, Biedl), Zellweger (1964 Zellweger), and CHARGE (1981 Hall/Hittner), the COL4A, BBS, PEX, and CHD7 genes, respectively, have been identified.
2. CausesAlport: COL4A3/A4/A5 variants (type IV collagen deficiency); Bardet-Biedl: BBS1–22 genes (ciliopathy); Zellweger: PEX gene family (peroxisome biogenesis disorder); CHARGE: CHD7 (10q22.3) variants (chromatin remodeling).
3. GeneticsAlport: X-linked (COL4A5), autosomal recessive (COL4A3/A4), autosomal dominant. Bardet-Biedl: autosomal recessive. Zellweger: autosomal recessive. CHARGE: mainly de novo autosomal dominant.
4. General epidemiologyAlport 1/50,000; Bardet-Biedl 1/150,000–1/160,000; Zellweger 1/50,000–1/100,000; CHARGE 1/8,500–1/12,000 births. All in the rare disease category.
5. PathophysiologyAlport: GBM type IV collagen deficiency → structural breakdown of the glomerular basement membrane → proteinuria and renal failure. Bardet-Biedl: ciliary dysfunction → multi-organ developmental abnormalities. Zellweger: failure of peroxisome biogenesis → neurodevelopmental and hepatic metabolic abnormalities. CHARGE: CHD7 defect → abnormal neural crest cell migration and differentiation.
6. SymptomsAlport: hematuria, proteinuria, progressive renal failure + sensorineural hearing loss + ophthalmic abnormalities. Bardet-Biedl: retinal degeneration, obesity, polydactyly, intellectual disability, renal abnormalities, reproductive abnormalities. Zellweger: hypotonia, hepatosplenomegaly, jaundice, seizures, neurological abnormalities. CHARGE: combined eye, heart, choanal, growth, genital, and ear abnormalities.
7. SignsAlport: urinary RBC casts, glomerular hematuria, high-frequency hearing loss. Bardet-Biedl: retinal pigmentation, polydactyly, obesity. Zellweger: characteristic facies, hepatosplenomegaly, neurological abnormalities. CHARGE: absent semicircular canals, choanal atresia, ear abnormalities.
8. ScreeningAlport: urine and renal function tests in children with family history + hematuria. Bardet-Biedl/CHARGE: gene panel after clinical criteria are met. Zellweger: plasma VLCFA measurement + peroxisomal enzyme tests.
9. DiagnosisAlport: renal biopsy EM (thinning/abnormality of the glomerular basement membrane). Bardet-Biedl: clinical criteria + BBS panel. Zellweger: VLCFA↑ + peroxisomal enzymes↓ + PEX variants. CHARGE: clinical criteria + CHD7 variant.
10. TreatmentAlport: renoprotection with RAAS inhibitors (sparsentan newly approved); Bardet-Biedl: symptomatic treatment of obesity and complications; Zellweger: symptomatic treatment (vitamin K, seizure control); CHARGE: multidisciplinary surgery and rehabilitation.
11. PrognosisAlport: end-stage renal disease in X-linked males in their 20s–30s; Bardet-Biedl: vision loss and renal failure are the main prognostic factors; Zellweger: most die before age 1; CHARGE: survival possible after correction of cardiac and airway abnormalities.
12. PreventionGenetic counseling, prenatal and preimplantation genetic diagnosis, early screening based on family history (Alport: urine monitoring; Bardet-Biedl: early renal and ophthalmic evaluation), prevention of renal complications with early RAAS administration.
13. References10 recent references (with PMID/DOI)

1. History

The Q87.8 code 'other specified congenital malformation syndromes (NEC)' covers complex congenital malformation syndromes not classified under the already specified Q87 subcategories, and the representative diseases included in this category, Alport syndrome, Bardet-Biedl syndrome, Zellweger syndrome, and CHARGE syndrome, each have an independent clinical history.

Alport syndrome was named when Arthur Cecil Alport of the UK reported cases in 1927 in which hematuria, progressive renal failure, and sensorineural hearing loss coexisted within a family. In 1985 Atkin et al. reported a defect of the type IV collagen α5 chain (COL4A5) of the glomerular basement membrane, and in 1990 Barker et al. identified COL4A5 (Xq22.3) as the causative gene of X-linked Alport syndrome. COL4A3 (2q36.3) and COL4A4 (2q36.3), the causative genes of the autosomal recessive form, were also identified subsequently.

Bardet-Biedl syndrome (BBS) was named when Georges Bardet of France in 1920 and Arthur Biedl of Austria in 1922 independently reported cases with retinitis pigmentosa, obesity, polydactyly, intellectual disability, and genital abnormalities. It was initially often confused with Laurence-Moon syndrome (described in 1866), but is now distinguished as a separate disease. Since the 2000s, numerous cilia-related genes ranging from BBS1 to BBS22 have been identified, and it has been reclassified as a ciliopathy.

Zellweger syndrome was named when the American pediatrician Hans Zellweger described in 1964 cases of infants with hypotonia, hepatosplenomegaly, and craniofacial abnormalities. In 1973 absence of peroxisomes was confirmed as a characteristic finding, and after variants in the PEX gene family encoding peroxisome biogenesis factors (peroxins) were identified as the cause, it was classified as the most severe form of peroxisome biogenesis disorder (PBD).

CHARGE syndrome was named when Hall and Hittner each reported, in 1979–1981, cases combining eye, heart, choanal, growth retardation, genital, and ear abnormalities (from the first letters of Coloboma, Heart defect, Atresia choanae, Retardation of growth/development, Genital abnormalities, Ear abnormalities). In 2004 Vissers et al. first identified CHD7 (10q22.3) gene variants as the main cause of CHARGE syndrome.

2. Causes

Alport syndrome

Alport syndrome is caused by pathogenic variants in the COL4A3 (2q36.3), COL4A4 (2q36.3), and COL4A5 (Xq22.3) genes, which encode the α3, α4, and α5 chains of type IV collagen in the glomerular basement membrane (GBM). The main component of the adult GBM is the α3·α4·α5 heterotrimer, and this structure maintains normal GBM filtration function and mechanical strength. X-linked Alport syndrome due to COL4A5 variants accounts for about 80% of the total, the autosomal recessive form due to COL4A3 or COL4A4 variants about 15%, and the autosomal dominant form (heterozygous COL4A3 or COL4A4 variants) about 5%.

Bardet-Biedl syndrome

It is caused by pathogenic variants in multiple genes responsible for ciliary structure and function (BBS1 to BBS22 or more to date). Genes encoding components of the BBSome (an intraciliary protein complex) are the most frequent, and BBS1 (11q13.2) variants are the most common single cause (about 20% of the total). BBS10 (12q21.2) variants are also frequently reported. It is a ciliopathy in which defective ciliary function causes combined abnormalities in all organs where cilia play a key role, such as visual cells (photoreceptors), renal epithelium, hypothalamic appetite-regulating cells, and genital development.

Zellweger syndrome

It is caused by pathogenic variants in the PEX gene family, which encodes peroxins essential for peroxisome biogenesis. PEX1 (7q21.2) variants are the most common, accounting for about 60% of PBD patients, and PEX6, PEX26, PEX12, PEX10, and others are also reported. When peroxisome assembly fails due to PEX gene variants, substances that must be metabolized in peroxisomes, such as very-long-chain fatty acids (VLCFA), phytanic acid, and bile acid precursors, accumulate, causing combined damage to neurodevelopment, liver function, and adrenocortical function.

CHARGE syndrome

The cause is pathogenic variants in the CHD7 (chromodomain helicase DNA binding protein 7) (10q22.3) gene. CHD7 is an ATP-dependent chromatin remodeling enzyme involved in transcriptional regulation of multiple genes during development. In particular, it plays a key role in neural crest cell migration and differentiation and in dorsal neural tube development. CHD7 variants are identified in about 60–70% of CHARGE syndrome patients, and the remainder have variants in other genes such as SEMA3E and EP300, or an unknown cause.

3. Genetics

The mode of inheritance of Alport syndrome differs by form. The X-linked form is due to COL4A5 variants; severe disease occurs with complete penetrance in males, and female carriers show mild to moderate hematuria, proteinuria, and progressive renal failure. The clinical severity of the X-linked form in females varies according to the X-chromosome inactivation (lyonization) pattern. The autosomal recessive form results from homozygous or compound heterozygous COL4A3 or COL4A4 variants, causing equally severe disease in males and females, and heterozygous carriers (parents) may show hematuria and proteinuria. The autosomal dominant form (heterozygous COL4A3 or COL4A4 variants) has a relatively mild phenotype, and progression to end-stage renal disease is less frequent but does occur.

Bardet-Biedl syndrome is inherited in an autosomal recessive manner. Homozygous or compound heterozygous variants in one gene are required. There is also a hypothesis that, rarely, an oligogenic mode of inheritance (a combination of variants in two or more genes) affects the clinical phenotype. The parents are carriers and asymptomatic.

Zellweger syndrome is also inherited in an autosomal recessive manner. It is caused by homozygous or compound heterozygous variants in a PEX gene. When both parents are carriers, the recurrence risk is 25%. Among PEX1 variants, the p.G843D variant shows a founder effect in some populations and tends to have a somewhat milder phenotype.

CHARGE syndrome occurs mainly as de novo autosomal dominant. About 90% or more are de novo CHD7 variants, and inheritance from a parent is rare (except when a parent has mild CHARGE syndrome). The recurrence risk for de novo variants is low, apart from the possibility of germline mosaicism (1–2%). Nonsense, splicing, missense, small insertion/deletion, and large deletion variants of CHD7 have all been reported. Genotype–phenotype correlation is incomplete, and clinical phenotypes vary greatly even with the same variant.

4. General epidemiology

The birth prevalence of Alport syndrome is estimated at about 1/50,000. It accounts for about 2.3% of causes of end-stage renal disease. The X-linked form accounts for about 80%, the autosomal recessive form about 15%, and the autosomal dominant form about 5%. About 90% of X-linked male patients reach end-stage renal disease before age 40. In Korea, too, it is one of the important hereditary causes of proteinuria and hematuria in children and adolescents.

The birth prevalence of Bardet-Biedl syndrome is about 1/150,000–1/160,000, but high frequencies due to founder effects are reported in certain populations (Iceland 1/13,500, Kuwaiti Bedouin 1/65,000). It occurs without sex difference.

The prevalence of Zellweger syndrome is about 1/50,000–1/100,000, and it is the most severe form within the peroxisome biogenesis disorder (PBD) spectrum. No sex difference. Because most die in the neonatal period to infancy, the number of prevalent patients is very small.

The birth prevalence of CHARGE syndrome is about 1/8,500–1/12,000, the highest frequency in the Q87.8 category. It occurs in all ethnic groups and regions worldwide without sex difference. As an important cause of multiple congenital anomalies, CHARGE syndrome must be ruled out in newborns with choanal atresia or complex congenital heart defects.

5. Pathophysiology

Alport syndrome

Type IV collagen is the main structural protein of basement membranes, with α1–α6 chains forming heterotrimers. In the adult GBM, the α3α4α5 heterotrimer is the main component, and this structure provides mechanical strength, a negative charge barrier, and filtration selectivity. When this heterotrimer is not produced due to COL4A3/A4/A5 variants, the GBM is replaced by the fetal α1α1α2 heterotrimer and becomes structurally fragile. As a result, the mechanical strength of the GBM decreases, and thinning, splitting, and lamellation are observed on electron microscopy. Hematuria results from passage of red blood cells through the GBM, and proteinuria arises from abnormal filtration function. Over time, glomerulosclerosis, interstitial fibrosis, and tubular damage progress, leading to end-stage renal disease. Sensorineural hearing loss arises from absence of the type IV collagen α3α4α5 heterotrimer in the cochlear basement membrane, and ophthalmic abnormalities (lenticonus deformity, macular abnormalities) arise from structural abnormalities of type IV collagen in the subretinal basement membrane.

Bardet-Biedl syndrome

Cilia are fine organelles projecting from the cell surface and are divided into primary cilia (non-motile, signal sensing) and motile cilia (motile, fluid movement). The BBSome is a protein complex involved in intraflagellar transport (IFT) within cilia. With BBS gene defects, abnormal IFT disrupts the movement of signaling receptors (Shh, PDGFRα, melanocortin receptors, etc.) into and out of cilia, causing combined functional abnormalities in cilia-dependent organs such as visual cells (photoreceptor cilia), renal collecting duct epithelium, hypothalamic appetite-regulating neurons, and cells involved in genital development. Obesity results from hyperphagia and reduced energy expenditure due to ciliary dysfunction in the hypothalamic melanocortin pathway.

Zellweger syndrome

Peroxisomes are single-membrane intracellular organelles responsible for essential metabolic functions such as VLCFA β-oxidation, phytanic acid α-oxidation, synthesis of ether phospholipids (plasmalogens), bile acid synthesis, and uric acid degradation. When peroxisome assembly fails due to PEX gene variants, all of these functions are lost. VLCFA accumulation damages myelin composition, causing abnormal cerebral myelination and neuronal migration disorders. Because plasmalogens are essential for maintaining neural membrane integrity, their deficiency severely affects central nervous system development. In the liver, VLCFA accumulation causes hepatocyte damage and jaundice, and in the adrenal cortex, VLCFA overload causes adrenal dysfunction.

CHARGE syndrome

CHD7 is an ATP-dependent chromatin remodeling enzyme that regulates transcription of developmental genes in the nucleus through nucleosome remodeling. A CHD7-dependent transcriptional program is essential for the migration, differentiation, and survival of neural crest cells early in embryonic development. With CHD7 deficiency, neural crest cell migration and differentiation fail, causing multiple malformations in organs derived from neural crest cells (ear, eye, cardiac outflow tract, face, genitalia, etc.). CHD7 is also involved in semicircular canal development, and in CHARGE syndrome, absence of the semicircular canals appears as a characteristic finding of vestibular dysfunction and abnormal canal formation.

6. Symptoms

Alport syndrome

The earliest symptom is microscopic hematuria, found in X-linked males from shortly after birth or infancy. Gross hematuria may recur after upper respiratory infections. Proteinuria appears as the disease progresses and in some cases progresses to nephrotic syndrome. Progressive decline in renal function occurs, and most X-linked males reach end-stage renal disease (requiring dialysis or kidney transplantation) in their 20s–30s. Sensorineural hearing loss first appears at high frequencies (2,000–8,000 Hz) and extends to lower frequencies as the disease progresses. Ophthalmic abnormalities may include anterior lenticonus and macular flecks.

Bardet-Biedl syndrome

6 major features: ① retinitis pigmentosa (begins with night blindness, progressive visual field constriction, eventual blindness), ② central obesity (develops from 1–2 years of age), ③ polydactyly (postaxial polydactyly of the hands and feet), ④ intellectual disability/developmental delay (mild to moderate), ⑤ genital abnormalities (male genital hypoplasia, female ovarian abnormalities), ⑥ renal abnormalities (renal cysts, urinary tract malformations, progressive decline in renal function). Diabetes, hypertension, and cardiac malformations are also frequently present.

Zellweger syndrome

From the neonatal period, severe hypotonia (floppiness), feeding difficulties, hepatosplenomegaly, jaundice, and characteristic craniofacial findings (high forehead, broad nasal bridge, hypertelorism) appear. Seizures (epilepsy) are common and worsen rapidly in the neonatal period. Renal cysts, chondral stippling (stippled calcification), abnormal cerebral myelination, and neuronal migration disorders are confirmed on imaging. Retinitis pigmentosa, optic nerve abnormalities, and sensorineural hearing loss also accompany it. Most die in the first year.

CHARGE syndrome

6 features: ① Eye (C): coloboma, microphthalmia, ② Heart (H): complex congenital heart defects (TOF, ventricular septal defect, patent ductus arteriosus, etc.), ③ Choanal atresia (A): unilateral or bilateral choanal atresia (a cause of neonatal respiratory distress), ④ Growth retardation (R): short stature and neurodevelopmental delay, ⑤ Genital abnormalities (G): cryptorchidism, micropenis, hypogonadism, ⑥ Ear abnormalities (E): ear dysplasia, absent semicircular canals (vestibular dysfunction), sensorineural hearing loss. In addition, cleft palate, esophageal dysmotility, and immunodeficiency (thymic hypoplasia) may be present.

7. Signs

Objective findings of Alport syndrome: urine microscopy shows dysmorphic RBCs and RBC casts, markers of glomerular hematuria. The urine protein/creatinine ratio increases along with declining renal function. Hearing tests (pure-tone audiometry, ABR) confirm high-frequency sensorineural hearing loss. Slit-lamp ophthalmic examination shows anterior lenticonus, which is a nearly pathognomonic finding in Alport syndrome. On electron microscopy of renal biopsy, GBM thinning (differentiation from thin basement membrane nephropathy required), irregular thickening, and lamellation (basket-weave pattern) are characteristic.

Findings of Bardet-Biedl syndrome: fundus examination shows retinal pigmentation (bone spicule shape), reduced reflex, and optic disc pallor. ERG (electroretinography) shows early reduction or loss of photoreceptor responses, and visual field testing confirms a ring scotoma and progressive visual field constriction. Physical examination reveals postaxial polydactyly (especially of the feet), obesity (especially central abdominal), and genital hypoplasia. Renal ultrasound confirms cysts and structural abnormalities, and blood tests also assess diabetes and lipid abnormalities.

Findings of Zellweger syndrome: on physical examination, characteristic facies (high forehead, hypertelorism, flat nasal bridge, small ears), severe hypotonia (frog-leg posture), hepatosplenomegaly. On blood tests, a marked increase in plasma VLCFA (C26:0, C24:0/C22:0 ratio, C26:0/C22:0 ratio) is the diagnostic abnormality. Decreased blood plasmalogen levels and increased phytanic acid are also confirmed. Brain MRI shows abnormal cerebral myelination, cortical heterotopia, and polymicrogyria. Abdominal ultrasound confirms renal cysts and hepatosplenomegaly.

Findings of CHARGE syndrome: neonatal choanal atresia is confirmed by nasal endoscopy or suspected when a thin catheter cannot pass through the nasal cavity. On ear CT, absence or hypoplasia of the semicircular canals is characteristic and is a useful supportive diagnostic finding for CHARGE syndrome. Ophthalmic examination: coloboma (iris, retinal, choroidal), microphthalmia. Echocardiography confirms complex cardiac malformations. Brain MRI shows absent olfactory nerves and semicircular canal hypoplasia.

8. Screening

Screening for Alport syndrome begins with family history and hematuria. Regular urine tests (hematuria, proteinuria) and renal function tests (serum creatinine, eGFR) are recommended in first-degree relatives (children, siblings) of patients with Alport syndrome. When glomerular hematuria (dysmorphic RBCs) is confirmed in a child with hematuria, Alport syndrome is included in the differential diagnosis and COL4A3/A4/A5 panel testing is performed along with a family history investigation. In the X-linked form, female carriers also require follow-up.

Screening for Bardet-Biedl syndrome begins with assessing whether clinical criteria are met. When 2–3 of polydactyly, central obesity, intellectual disability, and retinal abnormalities are combined, BBS is suspected and BBS gene panel testing is requested. Electroretinography (ERG) is useful for early objective assessment of retinal involvement. Renal function assessment (urine protein, eGFR) and renal ultrasound are also included in initial screening.

In screening for Zellweger syndrome, when it is suspected from the combination of neonatal hypotonia, characteristic facies, and hepatosplenomegaly, measurement of plasma VLCFA (C26:0) is the most useful and rapid screening test. When VLCFA elevation is confirmed, the PBD spectrum is diagnosed and confirmed by PEX gene panel testing. VLCFA measurement is being introduced into newborn screening programs in some countries.

Screening for CHARGE syndrome consists of evaluation of CHARGE syndrome clinical criteria and CHD7 gene testing in newborns with choanal atresia, complex congenital heart defects, or coloboma. When multiple congenital anomalies (cardiac + structural abnormalities) are found on prenatal ultrasound, early diagnosis is possible through prenatal genetic testing.

9. Diagnosis

Alport syndrome

Clinical diagnosis is based on the combination of glomerular hematuria + sensorineural hearing loss + family history. Molecular diagnosis is made by COL4A3/A4/A5 gene sequencing, and large deletions are confirmed by MLPA. On electron microscopy of renal biopsy, GBM thinning, irregular thickening, and lamellation (basket-weave) are characteristic. On immunofluorescence, loss (X-linked males) or reduction (X-linked females, autosomal recessive) of α5(IV) collagen is used for diagnosis. Noninvasive diagnosis is also possible by immunostaining of α5(IV) collagen in the epidermal basement membrane on skin biopsy.

Bardet-Biedl syndrome

Clinical diagnosis is by the Beales criteria (2001): 4 or more of the 4 primary criteria (retinal degeneration, polydactyly, obesity, intellectual disability/developmental delay, decreased renal function, genital abnormalities), or 3 + 3 or more secondary criteria. Pathogenic variants are identified by BBS gene panel (BBS1–22) sequencing, extended to WES if negative.

Zellweger syndrome

Elevated plasma VLCFA (C26:0, C24:0/C22:0 ratio) is the first step in diagnosis. In addition, the full extent of peroxisomal dysfunction is confirmed by measuring plasma phytanic acid, plasmalogens (ether phospholipids), and bile acid precursors. Diagnosis is confirmed by PEX gene panel (PEX1–PEX26, etc.) sequencing. It can be confirmed by fibroblast peroxisomal function tests (DHAP-AT activity, VLCFA β-oxidation).

CHARGE syndrome

Clinical diagnostic criteria for CHARGE syndrome (Blake criteria): 2 or more major criteria (absence/hypoplasia of the semicircular canals, coloboma, choanal atresia, characteristic ear anomalies), or 1 major criterion + 2 or more minor criteria (cardiac malformations, tracheoesophageal fistula, palatal anomalies, etc.). Confirmed by CHD7 gene sequencing, with deletions confirmed by MLPA/aCGH. Absence of the semicircular canals on ear CT has high diagnostic specificity.

10. Treatment

Alport syndrome

To date, causal treatment (gene therapy) remains at the preclinical stage, and the core of treatment is protection of renal function. RAAS inhibitors (ACE inhibitors or ARBs) slow the decline in renal function by reducing proteinuria and intraglomerular pressure, and early administration at or before the onset of proteinuria improves the renal prognosis. Sparsentan (a dual-acting drug with endothelin receptor blockade + AT1 blockade), approved by the FDA and EMA in 2023, demonstrated in clinical trials a significant reduction in proteinuria and a protective effect on eGFR in Alport syndrome. When end-stage renal disease is reached, it is treated with hemodialysis, peritoneal dialysis, or kidney transplantation. After kidney transplantation, renal function can be maintained with immunosuppression. For sensorineural hearing loss, hearing aids and cochlear implantation are used.

Bardet-Biedl syndrome

No curative treatment. Dietary and exercise guidance for obesity management and, in some cases, bariatric surgery are considered. Setmelanotide (an MC4R agonist), approved by the FDA in 2020, has shown meaningful weight loss in genetic obesity including BBS and can be prescribed. Early administration of RAAS inhibitors is recommended for declining renal function. There is no curative treatment for retinal degeneration, but low-vision aids, Braille education, and auditory communication training are needed. Developmental support and special education are also included.

Zellweger syndrome

There is no curative treatment, and all treatment is symptomatic. Vitamin K supplementation (correcting fat-soluble vitamin deficiency due to abnormal bile acid synthesis), seizure control with anticonvulsants, enteral nutrition (tube feeding), and liver-supportive care are provided. There is early evidence that docosahexaenoic acid (DHA) supplementation helps some patients with mild PBD, but its effect in the severe form of Zellweger syndrome is limited. Gene therapy clinical trials are underway for the mild form associated with certain founder variants (PEX1 p.G843D).

CHARGE syndrome

Multidisciplinary surgical and rehabilitative treatment is central. Bilateral choanal atresia in the neonatal period requires immediate airway securing (oropharyngeal airway, artificial airway insertion) and surgical choanal repair. Complex congenital heart defects are corrected by cardiac surgery. Cochlear implantation for sensorineural hearing loss can be performed even with accompanying vestibular dysfunction, but the rehabilitation prognosis is complex. For coloboma, ophthalmic surgery and refractive correction. Growth hormone therapy when growth hormone deficiency is present. Speech, cognitive, and behavioral rehabilitation and special education are included.

11. Prognosis

In Alport syndrome, about 90% of X-linked male patients reach end-stage renal disease before age 40, and studies show that early administration of RAAS inhibitors can delay the time to end-stage renal disease by an average of 10–15 years. Female carriers have a better renal prognosis, but 40% show some decline in renal function by age 60. The 5-year survival rate after kidney transplantation is about 90% or more, similar to general kidney transplant recipients. Sensorineural hearing loss is mostly progressive and can be corrected with cochlear implants.

In Bardet-Biedl syndrome, vision loss due to retinal degeneration is the greatest functional loss. Most reach legal blindness in their 20s–30s. Renal failure occurs in about 30–40% and requires dialysis or transplantation. Obesity-related complications (diabetes, hypertension, cardiovascular disease) affect life expectancy, and active weight management is important. Intellectual disability and behavioral problems affect social functioning and quality of life.

In Zellweger syndrome, most patients die within the first year of life from liver failure, seizures, or respiratory failure. Some milder forms (less severe on the PBD spectrum) survive for several years or more, but severe neurodevelopmental impairment persists.

The prognosis of CHARGE syndrome depends largely on the severity of cardiac malformations and airway anomalies. In patients who survive after correction of multiple malformations in the neonatal period, global developmental delay, hearing loss, and vision loss persist, and when multisensory impairment (vision + hearing) is present, communication and social participation are particularly limited. Multidisciplinary support, cochlear implantation, and auditory and visual rehabilitation contribute to improved quality of life.

12. Prevention

In the X-linked form of Alport syndrome, children of a carrier mother have a 50% transmission risk (50% of sons with severe disease, 50% of daughters carriers), so genetic counseling and prenatal genetic diagnosis are available. In the autosomal recessive form, when both parents are carriers, the recurrence risk is 25% and prenatal genetic diagnosis is used. Preimplantation genetic testing (PGT-M) allows selection of embryos before transfer. If there is a confirmed patient in the family, early urinalysis and genetic testing of siblings allow early detection of renal involvement, and early administration of RAAS inhibitors can slow the progression of renal failure.

Bardet-Biedl syndrome is autosomal recessive, with a 25% recurrence risk when both parents are carriers. Prenatal genetic diagnosis and PGT-M are available. After early diagnosis, retinal ERG screening detects retinal degeneration early, and starting low-vision rehabilitation early maximizes functional preservation. Regular monitoring of renal function is also important for early intervention in renal failure.

Zellweger syndrome is autosomal recessive, and prenatal genetic diagnosis and PGT-M are available. After parental carrier status is confirmed, fetal diagnosis is made in subsequent pregnancies by PEX gene analysis via CVS or amniocentesis. Introduction of newborn screening for plasma VLCFA in some countries contributes to early detection of PBD.

Because CHARGE syndrome is mostly due to de novo variants, most cases occur in the first child without a family history. The recurrence risk is low (germline mosaicism 1–2%), so the need for prenatal genetic diagnosis is limited, but if a case has already occurred, CHD7 gene analysis is available in subsequent pregnancies. Prenatal CHD7 genetic testing is recommended if prenatal ultrasound shows multiple congenital anomalies.

13. References

  1. Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018;93(5):1045-1051. PMID: 29551548
  2. Gross O, Licht C, Anders HJ, et al. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 2012;81(5):494-501. PMID: 22012136
  3. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437-446. PMID: 10359891
  4. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013;21(1):8-13. PMID: 22739346
  5. Haskell RE, Deen J, Loeffert D, Chaffin D. Gene therapy for Zellweger spectrum disorder: gene transfer and treatment paradigms. Mol Genet Metab. 2019;126(4):305-310. DOI: 10.1016/j.ymgme.2019.01.004
  6. Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab. 2016;117(3):313-321. PMID: 26750748
  7. Vissers LE, van Ravenswaaij CM, Admiraal R, et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet. 2004;36(9):955-957. PMID: 15300250
  8. Blake KD, Prasad C. CHARGE syndrome. Orphanet J Rare Dis. 2006;1:34. PMID: 16959034
  9. Connaughton DM, Hildebrandt F. Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant. 2020;35(3):390-397. PMID: 31834394
  10. Clémenson C, Coudon T, Moris G, et al. Setmelanotide for treatment of Bardet-Biedl syndrome and Alström syndrome. N Engl J Med. 2022;387(12):1136. DOI: 10.1056/NEJMoa2105896